Ocrelizumab co-formulated with rHuPH20

DRUG2 trials

Sponsors

Hoffmann-La Roche

Conditions

Multiple SclerosisRelapsing-remitting Multiple Sclerosis

Phase 1

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis

Active, not recruitingNCT07667322

Hoffmann-La RocheMultiple Sclerosis

Start: 2024-12-17End: 2028-08-01Target: 75Updated: 2026-08-13

Phase 3

A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)

Not yet recruitingNCT07503340

Hoffmann-La RocheRelapsing-remitting Multiple Sclerosis

Start: 2026-10-30End: 2031-08-01Target: 25Updated: 2026-09-03